Answers are grounded in this paper and cite their sources.
Genomic analysis reveals higher biomarker enrichment in non-small cell lung cancer with brain metastasis, indicating poorer outcomes.
NSCLC-BM showed higher genomic biomarker enrichment (80% vs. 68.68%) but poorer outcomes than mNSCLC. EGFR was the most common targetable mutation, followed by ALK in NSCLC-BM and KRAS in mNSCLC.
No takes yet. Share an insight, caveat, or question.
Rudresha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: